Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy.

Griffith TN, Varela-Nallar L, Dinamarca MC, Inestrosa NC.

Curr Med Chem. 2010;17(5):391-406. Review.

PMID:
20015041
2.

Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.

Hofrichter J, Krohn M, Schumacher T, Lange C, Feistel B, Walbroel B, Heinze HJ, Crockett S, Sharbel TF, Pahnke J.

Curr Alzheimer Res. 2013 Dec;10(10):1057-69.

3.

Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits.

Dinamarca MC, Cerpa W, Garrido J, Hancke JL, Inestrosa NC.

Mol Psychiatry. 2006 Nov;11(11):1032-48. Epub 2006 Jul 25.

PMID:
16880827
4.

[Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature].

Bouron A, Lorrain E.

Encephale. 2014 Apr;40(2):108-13. doi: 10.1016/j.encep.2013.03.004. Epub 2013 Jun 29. Review. French.

PMID:
23816060
5.

Role of hyperforin in the pharmacological activities of St. John's Wort.

Zanoli P.

CNS Drug Rev. 2004 Fall;10(3):203-18. Review.

6.

NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort.

Kumar V, Mdzinarishvili A, Kiewert C, Abbruscato T, Bickel U, van der Schyf CJ, Klein J.

J Pharmacol Sci. 2006 Sep;102(1):47-54. Epub 2006 Aug 26.

7.

Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels.

Leuner K, Kazanski V, Müller M, Essin K, Henke B, Gollasch M, Harteneck C, Müller WE.

FASEB J. 2007 Dec;21(14):4101-11. Epub 2007 Jul 31.

PMID:
17666455
8.

The hyperforin derivative IDN5706 occludes spatial memory impairments and neuropathological changes in a double transgenic Alzheimer's mouse model.

Cerpa W, Hancke JL, Morazzoni P, Bombardelli E, Riva A, Marin PP, Inestrosa NC.

Curr Alzheimer Res. 2010 Mar;7(2):126-33.

PMID:
19939230
9.
10.

St. John's wort.

Lawvere S, Mahoney MC.

Am Fam Physician. 2005 Dec 1;72(11):2249-54. Review.

11.

Hyperforin attenuates brain damage induced by transient middle cerebral artery occlusion (MCAO) in rats via inhibition of TRPC6 channels degradation.

Lin Y, Zhang JC, Fu J, Chen F, Wang J, Wu ZL, Yuan SY.

J Cereb Blood Flow Metab. 2013 Feb;33(2):253-62. doi: 10.1038/jcbfm.2012.164. Epub 2012 Nov 14.

12.

Current St John's wort research from mode of action to clinical efficacy.

Müller WE.

Pharmacol Res. 2003 Feb;47(2):101-9. Review.

PMID:
12543057
13.

Potential antidepressant properties of IDN 5491 (hyperforin-trimethoxybenzoate), a semisynthetic ester of hyperforin.

Cervo L, Mennini T, Rozio M, Ekalle-Soppo CB, Canetta A, Burbassi S, Guiso G, Pirona L, Riva A, Morazzoni P, Caccia S, Gobbi M.

Eur Neuropsychopharmacol. 2005 Mar;15(2):211-8.

PMID:
15695067
14.

Hyperforin: more than an antidepressant bioactive compound?

Medina MA, Martínez-Poveda B, Amores-Sánchez MI, Quesada AR.

Life Sci. 2006 Jun 6;79(2):105-11. Epub 2006 Jan 24. Review.

PMID:
16438991
15.

Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models.

Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H.

Life Sci. 2003 Jun 20;73(5):627-39.

PMID:
12770617
17.

Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study.

Muruganandam AV, Bhattacharya SK, Ghosal S.

Indian J Exp Biol. 2001 Dec;39(12):1302-4.

PMID:
12018529
18.

St. John's wort (Hypericum perforatum) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants.

Klier CM, Schmid-Siegel B, Schäfer MR, Lenz G, Saria A, Lee A, Zernig G.

J Clin Psychiatry. 2006 Feb;67(2):305-9.

PMID:
16566628
19.

The TRPC6 channel activator hyperforin induces the release of zinc and calcium from mitochondria.

Tu P, Gibon J, Bouron A.

J Neurochem. 2010 Jan;112(1):204-13. doi: 10.1111/j.1471-4159.2009.06446.x. Epub 2009 Oct 21.

20.

Protonophore properties of hyperforin are essential for its pharmacological activity.

Sell TS, Belkacemi T, Flockerzi V, Beck A.

Sci Rep. 2014 Dec 16;4:7500. doi: 10.1038/srep07500.

Supplemental Content

Support Center